 |
|
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clin Mol Hepatol. 2023;29(2):482-495. Published online 2023 Jan 5 DOI: https://doi.org/10.3350/cmh.2022.0322
|
|
Citations to this article as recorded by
 Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?
Yen-Chun Liu, Wen-Juei Jeng
Current Hepatology Reports.2024; 23(1): 11. CrossRef Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation
Jinglin Tang, Jiaxuan Zhang, Gaoli Zhang, Wenhui Peng, Ning Ling, Yingzhi Zhou, Hongmei Xu, Hong Ren, Min Chen, Marthandan Mahalingam, Swati Jain
mBio.2024;[Epub] CrossRef Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable?
Shasha Ma, Lian Zhou, Shutao Lin, Mingna Li, Jing Luo, Lubiao Chen
Diagnostics.2024; 14(5): 456. CrossRef Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis
Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim
JHEP Reports.2024; 6(7): 101089. CrossRef Inverse relationship between HBV DNA levels and liver histopathological changes in immune‐tolerant CHB patients
Deliang Huang, Huiyi Lai, Zhibin Zhu, Hong Yu, Jinghan Peng, Yuanyuan Chen, Xuejiao Liao, Jun Chen
Journal of Viral Hepatitis.2024; 31(7): 363. CrossRef Editorial: High qHBsAg—is it a good or bad signal?
Beom Kyung Kim
Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616. CrossRef Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase
Jian Wang, Li Zhu, Zhiyi Zhang, Shaoqiu Zhang, Yifan Pan, Yuanyuan Li, Fei Cao, Chao Jiang, Tao Fan, Ye Xiong, Jiacheng Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Chuanwu Zhu, Xingxiang Liu, Jie Li, Chao Wu, Rui Huang
Virology Journal.2024;[Epub] CrossRef Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis
Min Liu, Taixue Zhao, Jinyang Zhang, Bing Bu, Ruyi Zhang, Xueshan Xia, Jiawei Geng
Reviews in Medical Virology.2024;[Epub] CrossRef Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Joo Hyun Oh, Dong Hyun Sinn
Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Chia-Ming Chu, Yun-Fan Liaw
Clinical and Molecular Hepatology.2023; 29(2): 510. CrossRef The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Jeong-Ju Yoo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef Research Progress in Histological Features and Related Influencing Factors of Chronic Hepatitis B Patients with Persistent Normal ALT
宇行 刘
Advances in Clinical Medicine.2023; 13(05): 8702. CrossRef Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
Soon Kyu Lee, Jung Hyun Kwon
Clinical and Molecular Hepatology.2023; 29(3): 825. CrossRef
|